FIVE years of e-Scientific Publishing – Top Articles by e-Views >1,000 for all days ending 2018-01-29 (Summarized)
@pharmaceuticalintellicence.com
|
|
|
|
e-Readers
Views
All Time
1/29/2018
|
e-Readers
Views
All Time
4/27/2017 |
Author’s Name
|
|
|
521,463
|
445,321 |
|
| Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? |
16,114 |
15,461 |
Larry H. Bernstein, MD, FCAP |
| Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) |
11,606 |
10,005 |
Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
|
| Recent comprehensive review on the role of ultrasound in breast cancer management |
9,182 |
7,513 |
Dror Nir, PhD |
| Paclitaxel vs Abraxane (albumin-bound paclitaxel) |
8,781 |
6,721 |
Tilda Barliya, PhD |
| Our TEAM |
5,934 |
5,722 |
Aviva Lev-Ari, PhD, RN |
| Mesothelin: An early detection biomarker for cancer (By Jack Andraka) |
5,911 |
5,380 |
Tilda Barliya, PhD |
| Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care |
5,865 |
4,379 |
Aviva Lev-Ari, PhD, RN |
| Akt inhibition for cancer treatment, where do we stand today? |
4,333 |
4,077 |
Ziv Raviv, PhD |
| Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses |
3.962 |
3,847 |
Zohi Sternberg, PhD |
| Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications |
4,551 |
3,609 |
Aviva Lev-Ari, PhD, RN |
| Volume One: Perspectives on Nitric Oxide in Disease Mechanisms |
3,521 |
3,456 |
Larry H. Bernstein, MD, FCAP, Stephen J Williams, PhD, Aviral Vatsa, PhD, et al. |
| Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad |
3,558 |
3,330 |
Demet Sag, PhD |
| AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo |
3,305 |
3,215 |
Stephen J Williams, PhD |
| Founder |
3,257 |
3,131 |
Aviva Lev-Ari, PhD, RN |
| BioMed e-Series |
3,140 |
3,005 |
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN,
et al. |
| Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology |
3,064 |
2,866 |
Tilda Barliya, PhD |
| The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets |
3,138 |
2,854 |
Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN |
| Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I |
3,673 |
2,677 |
Larry H. Bernstein, MD, FCAP |
| VISION |
2,803 |
2,651 |
Aviva Lev-Ari, PhD, RN |
| Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community |
2,776 |
2,602 |
Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN |
| Funding, Deals & Partnerships |
2,601 |
2,506 |
Aviva Lev-Ari, PhD, RN |
| FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules |
2,946 |
2,461 |
Stephen J Williams, PhD |
| Bone regeneration and nanotechnology |
2,643 |
2,446 |
Tilda Barliya, PhD |
| Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging |
2,854 |
2,400 |
Dror Nir, PhD |
| “The Molecular pathology of Breast Cancer Progression” |
2,436 |
2,315 |
Tilda Barliya, PhD |
| Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation |
2,514 |
2,240 |
Larry H. Bernstein, MD, FCAP |
| Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) |
2,544 |
2,190 |
Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN |
| Targeting the Wnt Pathway [7.11] |
2,611 |
2,162 |
Larry H. Bernstein, MD, FCAP |
| In focus: Circulating Tumor Cells |
2,247 |
2,151 |
Ritu Saxena, PhD |
| Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) |
2,321 |
2,110 |
Justin D. Pearlman, MD, PhD, FACC
and
Larry H. Bernstein, MD, FCAP |
| AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation |
3,458 |
2,100 |
Stephen J Williams, PhD |
| Journal PharmaceuticalIntelligence.com |
2,214 |
2,068 |
Aviva Lev-Ari, PhD, RN and et al. |
| About |
2,054 |
2,044 |
Aviva Lev-Ari, PhD, RN |
| Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment |
2,456 |
2,028 |
Sudipta Saha, PhD |
| Interaction of enzymes and hormones |
2,654 |
1,994 |
Larry H. Bernstein, MD, FCAP |
|
|
1,925 |
1,908 |
Sudipta Saha, PhD |
| DNA Structure and Oligonucleotides |
2,016 |
1,905 |
Larry H. Bernstein, MD, FCAP |
| Biosimilars: CMC Issues and Regulatory Requirements |
1,953 |
1,813 |
Aviva Lev-Ari, PhD, RN |
| CD47: Target Therapy for Cancer |
1,907 |
1,763 |
Tilda Barliya, PhD |
| Lipid Metabolism |
1,968 |
1,761 |
Larry H. Bernstein, MD, FCAP |
| Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes |
1,919 |
1,761 |
Aviva Lev-Ari, PhD, RN |
| Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) |
2,189 |
1,725 |
Tilda Barliya, PhD |
| Non-small Cell Lung Cancer drugs – where does the Future lie? |
1,867 |
1,720 |
Ritu Saxena, PhD |
| A Primer on DNA and DNA Replication |
2,001 |
1,720 |
Larry H. Bernstein, MD, FCAP |
| Introduction to Tissue Engineering; Nanotechnology applications |
1,998 |
1,711 |
Tilda Barliya, PhD |
| Nanotechnology: Detecting and Treating metastatic cancer in the lymph node |
1,767 |
1,667 |
Tilda Barliya, PhD |
| Nitric Oxide Function in Coagulation – Part II |
1,965 |
1,614 |
Larry H. Bernstein, MD, FCAP |
| The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research |
1,795 |
1,603 |
Stephen J Williams, PhD |
| FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® |
2,059 |
1,578 |
Aviva Lev-Ari, PhD, RN |
| Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB |
1,561 |
1,542 |
Aviva Lev-Ari, PhD, RN |
| The role of biomarkers in the diagnosis of sepsis and patient management |
1,659 |
1,500 |
Larry H. Bernstein, MD, FCAP |
| Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers |
1,513 |
1,475 |
Aviva Lev-Ari, PhD, RN |
| Nanotechnology and MRI imaging |
1,574 |
1,470 |
Tilda Barliya, PhD |
| Baby’s microbiome changing due to caesarean birth and formula feeding |
1,492 |
1,457 |
Aviva Lev-Ari, PhD, RN |
| Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions |
1,598 |
1,453 |
Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN |
| Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays |
1,472 |
1,424 |
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN |
| Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? |
1,472 |
1,417 |
Aviva Lev-Ari, PhD, RN |
| Neonatal Pathophysiology |
1,562 |
1,412 |
Larry H. Bernstein, MD, FCAP |
| Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) |
1,518 |
1,408 |
Aviva Lev-Ari, PhD, RN |
| Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases |
1,527 |
1,396 |
Justin D. Pearlman, MD, PhD, FACC |
| IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase |
1,423 |
1,384 |
Demet Sag, PhD |
| UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack |
1,407 |
1,360 |
Aviva Lev-Ari, PhD, RN |
| Monoclonal Antibody Therapy and Market |
1,854 |
1,352 |
Demet Sag, PhD |
| Mitochondrial Damage and Repair under Oxidative Stress |
1,355 |
1,315 |
Larry H. Bernstein, MD, FCAP |
| Closing the Mammography gap |
1,325 |
1,292 |
Dror Nir, PhD |
| Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease |
1,374 |
1,288 |
Aviva Lev-Ari, PhD, RN |
| Update on FDA Policy Regarding 3D Bioprinted Material |
2,011 |
1,286 |
Aviva Lev-Ari, PhD, RN |
| Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? |
1,493 |
1,276 |
Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN |
| Aviva Lev-Ari, PhD, RN, Director and Founder |
1,317 |
1,250 |
Aviva Lev-Ari, PhD, RN |
| Diagnostic Evaluation of SIRS by Immature Granulocytes |
1,328 |
1,249 |
Larry H. Bernstein, MD, FCAP |
| Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) |
1,400 |
1,238 |
Larry H. Bernstein, MD, FCAP |
| Signaling and Signaling Pathways |
2,598 |
1,235 |
Larry H. Bernstein, MD, FCAP |
| Crucial role of Nitric Oxide in Cancer |
1,309 |
1,215 |
Ritu Saxena, PhD |
| Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes |
1,339 |
1,211 |
Aviva Lev-Ari, PhD, RN |
| Mitochondrial fission and fusion: potential therapeutic targets? |
1,230 |
1,203 |
Ritu Saxena, PhD |
| Diet and Diabetes |
1,370 |
1,186 |
Larry H. Bernstein, MD, FCAP |
| Mitochondrial Dynamics and Cardiovascular Diseases |
1,225 |
1,171 |
Ritu Saxena, PhD |
| Nanotechnology and Heart Disease |
1,300 |
1,159 |
Tilda Barliya, PhD |
| Nitric Oxide and Immune Responses: Part 2 |
1,186 |
1,153 |
Aviral Vatsa, PhD |
| Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery |
1,182 |
1,153 |
Aviva Lev-Ari, PhD, RN |
| The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments |
1,217 |
1,149 |
Larry H. Bernstein, MD, FCAP |
| ‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly |
1,151 |
1,128 |
Aviva Lev-Ari, PhD, RN |
| Scientific and Medical Affairs Chronological CV |
1,336 |
1,127 |
Aviva Lev-Ari, PhD, RN |
| Assessing Cardiovascular Disease with Biomarkers |
1,146 |
1,122 |
Larry H. Bernstein, MD, FCAP |
| Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing |
1,127 |
1,116 |
Stephen J Williams, PhD |
| Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors |
1,167 |
1,112 |
Stephen J Williams, PhD |
| Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function |
1,146 |
1,111 |
Larry H. Bernstein, MD, FCAP |
| Nanotechnology and HIV/AIDS treatment |
1,160 |
1,109 |
Tilda Barliya, PhD |
| Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin |
1,230 |
1,107 |
Aviva Lev-Ari, PhD, RN |
| Ultrasound-based Screening for Ovarian Cancer |
1,269 |
1,105 |
Dror Nir, PhD |
| Stenting for Proximal LAD Lesions |
1,345 |
1,082 |
Aviva Lev-Ari, PhD, RN |
| Treatment of Refractory Hypertension via Percutaneous Renal Denervation |
1,085 |
1,082 |
Aviva Lev-Ari, PhD, RN |
| Nitric Oxide and it’s impact on Cardiothoracic Surgery |
1,268 |
1,079 |
Tilda Barliya, PhD |
| Wnt/β-catenin Signaling [7.10] |
1,480 |
1,078 |
Larry H. Bernstein, MD, FCAP |
| Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism |
1,174 |
1,068 |
Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN |
| Unique Selling Proposition (USP) — Building Pharmaceuticals Brands |
1,342 |
1,063 |
Aviva Lev-Ari, PhD, RN |
| Patiromer – New drug for Hyperkalemia |
1,113 |
1,054 |
Aviva Lev-Ari, PhD, RN |
| Isoenzymes in cell metabolic pathways |
1,462 |
1,048 |
Larry H. Bernstein, MD, FCAP |
| Sex Hormones |
1,391 |
1,039 |
Larry H. Bernstein, MD, FCAP |
| LPBI Group |
1,201 |
1,027 |
Aviva Lev-Ari, PhD, RN |
| Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty |
1,227 |
1,027 |
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN |
| Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I |
1,031 |
1,020 |
Aviral Vatsa, PhD |
| Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents |
1,049 |
1,015 |
Aviral Vatsa, PhD |
| Ovarian Cancer and fluorescence-guided surgery: A report |
1,167 |
1,012 |
Tilda Barliya, PhD |
| Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation |
1,059 |
1,012 |
Aviva Lev-Ari, PhD, RN |
| Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model |
1,045 |
1,011 |
Anamika Sarkar, PhD |
| New England Compounding Center: A Family Business |
1,064 |
1,008 |
Alan F. Kaul, PharmD |
| Integrins, Cadherins, Signaling and the Cytoskeleton |
1,498 |
1,003 |
Larry H. Bernstein, MD, FCAP |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
FrasonKalapurackal
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
[…] https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceutic… […]